Bavencio misses primary in Phase III for advanced gastric cancer

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said PD-L1 mAb Bavencio avelumab (MSB0010718C, PF-06834635) missed the primary endpoint in the Phase III JAVELIN Gastric

Read the full 242 word article

User Sign In